An interventional study of Nurse-led telehealth remote self-monitoring in Rheumatoid Arthritis (RA), sponsored by CHU de Quebec-Universite Laval. Not yet recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Arthritis, Rheumatoid with a site in Canada — 17 open to participants now, 32 under way, 3 of them phase 3. Arthritis, Rheumatoid · Canada.
Among the 251 studies in Arthritis, Rheumatoid with a site in Canada, this one is the 173rd largest by planned enrollment of the 214 interventional ones that give a count, is the only one that started in 2027, is one of 34 with no phase, reaches primary completion later than 24 of the 31 other live ones, and was the 250th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →17 of the 251 studies in Arthritis, Rheumatoid with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 14 more countries
Ages 18+
AbbVie · Sites in Canada, United States, Czechia and 9 more countries
Ages 18+
Western University, Canada · Sites in Canada
Ages 18–80
AstraZeneca · Sites in Canada, United States, China and 7 more countries
Ages 18–70
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 61 · Phase 3 92 · Phase 4 22
First in 1996; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is close to the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 303 across the 214 interventional studies, 211 across the 36 observational. Of the 207 that completed or were terminated, 131 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
202 of 251 have an industry lead sponsor. The 10 most frequent:
CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.
CHU de Quebec-Universite Laval has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
7 of the studies in Arthritis, Rheumatoid with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT02038140Zimmer BiometZimmer Trabecular Metal Total Ankle PMCF | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 251 studies in Arthritis, Rheumatoid with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology.
The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable.
This new approach involves nurses helping patients check their own health from home using an online platform.
104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages.
This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.
Background: Limited access to rheumatologists in Canadian remote regions leads to delays in new-onset rheumatoid arthritis (RA) diagnosis and inadequate follow-up for disease flares or treatment adjustments. There is a critical need for innovative models of care addressing these unmet needs in resource-limited settings. E-health technologies offer a promising solution by bridging the gap between in-person rheumatology appointments. These tools can optimize the use of scarce specialist resources, enhance the continuity and quality of care, and provide greater convenience for patients-particularly in underserved or geographically isolated areas. By supporting timely interventions and patient-centered monitoring, e-health can play a vital role in improving outcomes and ensuring equitable access to care.
Objectives: This study will evaluate the acceptability and feasibility of a nurse-led telehealth remote self-monitoring model of care for patients with RA.
Primary Objective: Acceptability of a nurse-led telehealth remote self-monitoring program, defined as patient-reported perceptions of usefulness, ease of use, attitudes, and overall experience, and assessed with questionnaires and semi-structured interviews.
Secondary Objectives: Feasibility using the RE-AIM implementation framework:
Methods - The investigators will recruit 104 adults with RA who experienced a flare or required a DMARDs switch within the preceding three months, from 4 rheumatology practices (community and academic sites) providing care to >15,000 RA patients. All participants will be randomized 1:1 to receive either immediate intervention (for 16 months) or delayed, i.e. usual care for 8 months (control period) followed by 8 months of intervention, consisting of remote self-monitoring using a web platform co-developed with patients, rheumatologists, and nurses. Rheumatology visits will be scheduled every 3-6 months, with additional visits as necessary. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available. Data will be collected using questionnaires and semi-structured interviews. Analysis will use quantitative (generalized linear mixed-effect models comparing within group changes [8 months - baseline, both groups combined] and between groups differences [intervention versus control] in continuous variables), and qualitative methods (thematic content analysis by two independent researchers).
Impact and feasibility. A nurse-led remote self-monitoring of RA using a web-based platform codeveloped with patient input, has potential to enhance access to care and more efficiently use scarce rheumatology resources while providing high quality care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.
Other: Nurse-led telehealth remote self-monitoring
Usual care for 8 months, consisting in rheumatology visits scheduled every 3-6 months. Followed by the intervention for 8 months: The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.
Other: Nurse-led telehealth remote self-monitoring
Remote self-monitoring will use a web platform co-developed with patients, rheumatologists, and nurses. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.
Acceptability of the intervention evaluated by a questionnaire
The questionnaire of patients' perceived usefulness and ease of use of the remote self-monitoring web platform will be completed by participants at 16 months, rated using a 13-item questionnaire utilizing five-point Likert scales.
Time frame: At 16 months
Acceptability of the intervention evaluated by a qualitative analysis
Semi-structured interviews with patients and providers will be completed with a purposive sample of participants (diverse with respect to age, gender, ethnicity, education, disease type and duration, employment, urban/rural) at study end. Participants will meet in groups of 8-12 for 60-90 minutes; groups will continue until saturation of themes is obtained (estimated to be 2-3 groups). Topics will include perceived acceptability, convenience, satisfaction, beliefs, perceived usefulness and ease of use, how care received met patient needs, barriers and enablers to adopting this new model of care.
Time frame: At 16 months
Age category of eligible participants
Age category of eligible patients
Time frame: Until the end of recruiting period
Frequency of calls to nurses
Frequency of calls to nurses will be collected on the electronic medical record of each rheumatology clinic
Time frame: Up to the end of intervention at 16 months
Use of other health care services
Self-reported by patients in a survey administered every three months, including emergency room visits, hospitalizations, visits to primary care physicians, other specialists, other healthcare professionals.
Time frame: Every 3 months over 16 months
Health-related quality of life evaluated by the Patient-Reported Outcomes Measurement Information System-29 questionnaire
Measured by the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) which is a patient-reported measure of symptoms and function validated in French, which includes four items from each of seven domains (physical function, depression, anxiety, fatigue, sleep disturbances and ability to participate in social roles and activities, pain interference) and a single item on pain intensity. It has been co-developed with patients and validated in rheumatic diseases. Each item has five response options, except for pain which has eleven. A total score is calculated for each domain from the sum of item answers. Range from 20 to 80.
Time frame: Every 3 months over 16 months
Disease activity evaluated by the Clinical Disease Activity Index
Measured using Clinical Disease Activity Index (CDAI) at every 3-6 months rheumatology follow-up visit The CDAI is the sum of the count of swollen/tender joint count of 28 joints and patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76.
Time frame: Every 3 to 6 months over 16 months
Proportion of medication adherence
The proportion of adherence will be calculated by dividing the quantity received by the quantity prescribed for each month starting three months before enrollment until six months after. The mean proportion of adherence per medication will be calculated for each time period by taking the mean of all months included in each of the periods. For each of these periods, the patient will be considered adherent if the mean is greater or equal to 80%.
Time frame: Every 3 months up to the end of intervention over 16 months
Completion rate of patient questionnaires for remote self-monitoring
Completion rate of patient questionnaires for remote self-monitoring (Rheumatoid Arthritis Disease Activity Index RADAI and Patient-Reported Outcomes Measurement Information System-29, PROMIS-29)
Time frame: Every month during the intervention over 16 months
Proportion of participants still connecting to the web platform at study end
Proportion of participants still connecting to the web platform at study end
Time frame: At 16 months
Time spent on the web platform
Time spent on the web platform by each participant
Time frame: Up to the end of intervention at 16 months
Measuring the number of alerts per patient
Measuring the number of alerts per patient
Time frame: Up to the end of intervention at 16 months
Questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system
Rheumatology nurses, rheumatologists, and administrative staff will answer the questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system, a 33-item anonymous survey on their intended sustained use of nurse-led remote self-monitoring with a 7-point likert scale for each questions.
Time frame: At 16 months
Sex category of eligible patients
Sex category of eligible patients
Time frame: Up to the end of recruiting period
Clinical appropriateness of alerts
Clinical appropriateness of alerts based on rheumatology team subsequent actions (ex: timeliness of in-person visits, whether triggered visits led to medication change)
Time frame: Up to the end of intervention over 16 months
Number of nurse-patient interactions
Number of nurse-patient interactions using the platform
Time frame: Up to the end of intervention over 16 months
Reason for nurse calls
Reason for nurse calls will be collected on the electronic medical record of each rheumatology clinic
Time frame: Up to the end of intervention at 16 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2028, 16 months later.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 16 months is below that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start May 2026 → Jan 2027, primary completion Sep 2027 → May 2028 and completion Dec 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Quebec-Universite Laval →